PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Ann Oncol
; 29(10): 2151, 2018 10 01.
Article
em En
| MEDLINE
| ID: mdl-29701763
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article